Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Prothena Corporation plc

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Third Quarter 2023 Financial Results on November 2
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Second Quarter 2023 Financial Results on August 3
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Participate in Jefferies 2023 Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report First Quarter 2023 Financial Results on May 4
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Participate in 2023 Bank of America Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Participate in Stifel 2023 Virtual CNS Days
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Proposed Public Offering of Ordinary Shares
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
From Prothena Corporation plc
Via GlobeNewswire
Tickers PRTA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.